FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The review of Vanda’s Fanapt casts into relief the contours of FDA’s authority to consider comparative efficacy as a factor in drug approval decisions.